This website uses cookies. By continuing you are agreeing to our privacy policy.

Clinical Trials

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer


Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center


Multi-Center Trial


The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with pembrolizumab immunotherapy in patients with metastatic non-small cell lung cancer. Pembrolizumab works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Guadecitabine and mocetinostat are “epigenetic therapies” that work on certain genes that may be turned on or off in cancer. Pembrolizumab is given intravenously (by vein). Guadecitabine is given by subcutaneous (under the skin) injection, and mocetinostat is taken orally (by mouth).


August 4, 2017 - July 31, 2020


Lung Cancer


By center:

Memorial Sloan Kettering
Matthew Hellman, MD
[email protected]

Fox Chase
Hossein Borghaei, MS, DO
[email protected]
888-369-2427 or 215-214-4297

Johns Hopkins
Jarushka Naidoo, MBBCh
[email protected]

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.